alexa Trastuzumab-related cardiotoxicity among older patients with breast cancer.
Oncology

Oncology

Advances in Oncology Research and Treatments

Author(s): ChavezMacGregor M, Zhang N, Buchholz TA, Zhang Y, Niu J,

Abstract Share this page

Abstract PURPOSE: The use of trastuzumab in the adjuvant setting improves outcomes but is associated with cardiotoxicity manifested as congestive heart failure (CHF). The rates and risk factors associated with trastuzumab-related CHF among older patients are unknown. PATIENTS AND METHODS: Breast cancer patients at least 66 years old with full Medicare coverage, diagnosed with stage I-III breast cancer between 2005 and 2009, and treated with chemotherapy were identified in the SEER-Medicare and in the Texas Cancer Registry-Medicare databases. The rates and risk factors associated with CHF were evaluated. Chemotherapy, trastuzumab use, comorbidities, and CHF were identified using International Classification of Diseases, version 9, and Healthcare Common Procedure Coding System codes. Analyses included descriptive statistics and Cox proportional hazards models. RESULTS: In total, 9,535 patients were included, of whom 2,203 (23.1\%) received trastuzumab. Median age of the entire cohort was 71 years old. Among trastuzumab users, the rate of CHF was 29.4\% compared with 18.9\% in nontrastuzumab users (P < .001). Trastuzumab users were more likely to develop CHF than nontrastuzumab users (hazard ratio [HR], 1.95; 95\% CI, 1.75 to 2.17). Among trastuzumab-treated patients, older age (age > 80 years; HR, 1.53; 95\% CI, 1.16 to 2.10), coronary artery disease (HR, 1.82; 95\% CI, 1.34 to 2.48), hypertension (HR, 1.24; 95\% CI, 1.02 to 1.50), and weekly trastuzumab administration (HR, 1.33; 95\% CI, 1.05 to 1.68) increased the risk of CHF. CONCLUSION: In this large cohort of older breast cancer patients, the rates of trastuzumb-related CHF are higher than those reported in clinical trials. Among patients treated with trastuzumab, those with cardiac comorbidities and older age may be at higher risk. Further studies need to confirm the role that the frequency of administration plays in the development of trastuzumab-related CHF.
This article was published in J Clin Oncol and referenced in Advances in Oncology Research and Treatments

Relevant Expert PPTs

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords